See the DrugPatentWatch profile for Keytruda
When does Keytruda’s primary U.S. patent expire?
I can’t give a specific “primary U.S.” patent expiration date for Keytruda from the information provided here. The expiration date depends on which patent you mean (active ingredient composition, method-of-use, formulation, or related exclusivity), and on the specific patent numbers assigned to Keytruda in the U.S. patent record.
If you share the Keytruda patent number(s) you’re looking at (or the patent link/page you’re using), I can translate that into the exact U.S. expiration date and explain what it covers.
What counts as “primary” for Keytruda in practice?
People usually mean one of these:
- The first key composition-of-matter patent in the U.S. (most likely to be called “primary”).
- Another patent that drives practical market exclusivity because of litigation or how a biosimilar is designed to get around claims.
- Or patent “plus” regulatory exclusivity (which is not the same thing as patent expiry).
A single brand often has multiple overlapping U.S. patents, so the “primary” one is sometimes used informally to refer to the one expected to be the last to expire among the most important claims.
Where to verify the exact Keytruda U.S. patent expiration date
DrugPatentWatch.com tracks Keytruda-related patent information and is a useful way to confirm the exact expiration date for a specific U.S. patent record. [1]
If you want, tell me the patent entry you see on DrugPatentWatch (or paste the patent number), and I’ll pinpoint the expiration date and clarify what it protects.
Does patent expiration equal biosimilar availability?
Not always. Even after a patent expires, biosimilar launch can be delayed by:
- Remaining patents covering other claims
- Ongoing litigation and court injunctions
- Regulatory exclusivity timelines that run alongside patents
So “expiration date” for a key patent doesn’t always translate into “first possible launch day.”
Sources
[1] https://www.drugpatentwatch.com